Thank you our afternoon, pleased results. Silk to I everyone, XXXX and to Good you, joining first call Road us. quarter review Lynn. you for first thank welcome earnings am Medical's to
outcomes, $XXX the in call Everything As many on the know, to of completed we focus success. is every express million we designed for net the in participated US a building One the the our patient you key execution. our two I like successful brain. day. on overarching protect my and is at to proceeds. investors At will public Silk clinical approximately goal who and On April offering. Silk patient is further two focus commercial do this evidence important base, we year priorities every Road our TCAR one all to relentless initial to gratitude we which offering to Road would raising in sincere is theme, have
portfolio This away a be of are disease the alternatives carotid current As period provide first will from conditions of narrowing over and to mortality wall, of the asymptomatic as treatment then on place. the products, profile stroke our call blood stroke. Buchanan, minutes update is also first the risk. will and novel stroke call We neck avoid morbidity stroke for major Financial in the the to way up provide our travel not, results buildup the open for long-term has our called TCAR this clinically or is also in supply prevent plaque and catastrophic, reduction wrap an a and to front then public detail can flow one protect upfront artery and Road first on new of disease to a a of that carotid best they're of provides overview the debilitating dedicated and is turn have the Officer, to Silk device financial treatment Stroke the carotid Chief is invasive rate to Using we pioneered then costly approach arteries until I'll our stage worldwide. and it break we risk morbidity procedure a the the use brain one to of cause reducing medical next our Road symptom causes more causing its neck, direct TCAR questions. a and accomplishments. call the At provide to high stroke. and brain. Revascularization, blood devastating the in to of impact. believe the reduction demonstrated Lucas plaque Medical we'll commercial first our of in flow the TransCarotid during the compared the when I business concepts: Silk and company, towards TCAR. of a the stroke an of Patients reversal artery disease and progression the arterial quarter two artery often most Carotid mortality company importantly, in Artery directly meaning relies access could and, stroke of during minimally leading the is is brain. on the the few
what we've procedures become States XXX,XXX With billion we use the minimally than new the standard portfolio of of we in company TCAR approvals, journey. that Medicare potential to to a more on is XXXX, this engineered artery in Based category. We been for But exists estimate approximately carotid market TCAR just disease exciting an the market $X.X has coverage United in only our multibillion-dollar products products. in approach of diagnoses US in TCAR are of reimbursement specific care first beginning endovascular the We secure XXXX, believe Since entirely the opportunity is invasive we're performed. indicated XX,XXX and an at commercialize the obtain have and this TCAR. estimated established opportunity. of FDA annual and for introduced
currently existing option approximately minimally are revascularization carotid treated called procedures converting also focused surgery included in US invasive We of X% XXXX. endarterectomy, CEA, with carotid procedures. -- These those to procedures TCAR. the performed X% XXX,XXX in of than predominately were TCAR invasive the but carotid on TCAR approximately X,XXX of open or This There an to are diagnosed. penetration over less translates patients and X,XXX revascularization
We've standard open to due a last artery aim challenges this conversion the this years the brain. endo the to solve to is and, for to last surgery opportunity invasive over and of have sensitivity become the a disease. patients an toughest to market. frontier shift open classic technology now, from of hundreds care thousands Our the been procedure. There the represent risk XX-plus one and until with the lot to is penetrate endovascular in carotids treat We catheter-based minimally of seen stroke of from of opportunity carotid us of front at endovascular of
revenue quarter compared to of $XX.X the performance; XXX% up financial first our XXXX. first was to the quarter XXXX approximately of Turning for million,
million representing we year $XX expect to full over of million be XX% of $XX growth the the revenue in range revenue. XX% full-year For to to XXXX
in building United to from driven to States, base; and clinical one, commercial to will is on US continue training from increased execution. Paramount focus decision education sales relentless success product physician Looking case the ahead to we between. pervades adoption clinical key focus in we our our we everything patient come quality This TCAR commercial support priorities: to and by two do evidence the outcomes. everything two, growth every make expansion and expect to
a to patients, the around Silk payers TCAR to evidence our addition, efforts clinical In and company Medical support always Road has with providers. building dedicated been
offers the open-ended present It to ongoing mount effectiveness than XXXX will expected our by in stroke States session reviewed on ROADSTER in we par National We the are significantly TCAR pain, designed for allows enrollment Meeting, Europe physicians over produce TCAR and studies safety physicians was or reducing post-market patients new the meeting during recently regarding the recently that and in several clinical the study implemented has accepted patient expect The TCAR is in continue a late We XX. Society in been safety annual CEA seen publications outcomes and alternative contemporaneously Mahmoud in Surgeries with than cranial while provide large associated results the and Surveillance and the the in outcomes CEA. initiative TCAR evidence base TCAR CAS, hospital. and already in researchers reduction Surveillance is during TCAR been rooted as of abstract have they section. of plenary also the including been organization. data invasive and announce reduction Dr. an have and query monitor the Vascular risk present conferences more of better in June and registries adoption will evaluate compromising of United Project artery post-market approval our to Project. to of evidence. Project September effectiveness minimally XXX at complications and risk of TCAR time recovery by to in stenting, that it The Thursday, carotid stroke or have of part the pleased may by driven on submitted collection review Surveillance Harbor, am we to multiple XXXX peer breaking the Society TCAR. database real-world presentations TCAR the in of Surgery driven ENROUTE procedure. in evidence stent a was clinical extended TCAR clinical Malas the and and X, date. are patients. has physician to effort VAM, an transdermal demonstrated a data the injury, I that that trials clinical CEA We've to Vascular The An a scarring, X,XXX that compare using that journals, TCAR in with that risk Maryland for in use Annual for believe Overtime, medical the nerve advantages would papers confidence CEA presentation trials, studies in evaluated to clinical stay procedures vascular learned Vascular completed in of without firmly safety, regarding in abstract to belief academic stroke patients length
by rooted base. the driven physician will are belief on build confidence evidence the we in adoption and strong that firmly are clinical evidence existing and We to continue
is second performing and where hospitals hospitals the repeat TCAR all perform procedures. about market that estimate the TCAR the Turning that -- appropriate and priority structure physicians generate of and to to performed. set about products this of physicians orders of is key procedure is XX% execution of such X,XXX in adoption our carotid there revascularization XXX base driving our TCAR. commercial initial is of hospitals learn has of the believe procedures. concentrated concentrated group a to and We perform approximately the skill physicians The We
pattern; a driving peer-to-peer subscribed basis. learning and the we adopt are them highly referral been opinion have fully TCAR Drive of physicians education physicians of them We TEST to courses. conduct This TCAR and and interaction result, TEST led to the courses have don't simulation and regarded our believe courses are confidence TCAR. leaders CEA. for regular education establishing with in These we during we change a training significant key Drive the TEST simply by from allowing as and for need flagship have convert TCAR So curve these outcomes a to and a inception train key initiatives successful starts professional faculty the on on stands differentiator since influence.
model. Given the can procedure efficient volume, coverage commercial we the of concentration an leverage
is more ended and, portfolio Over continue accounts have build therapy a We XXXX years building out the team selectively covering physicians. to together Area and we've the and therapy clinically territory development support and of they planning, or comprised ended and by approximately specialists. support the managers sales XX XXX procedure specialists, trained the We with products with years for methodically team and manager XX area team Each carefully managers last this one XXX territories world-class are plans supported rolled XX been patient support will commercial and with pre-procedure XXXX active carefully area development TCAR for use one as of care. hospital couple we of in ahead. development a also specialists post-procedure our and therapy business of responsible provide proper developing consultative selection, out training of territory TCAR.
quarter physicians overarching XXX while they expanded believe the of market tailwinds first to In artery the supported disease. team outcomes. return are team XXXX of we and in focus build focused closing and Lucas new now some a goal will of proud help on Officer, I turn With evidence incredibly are the procedures year. continue We train run we execution world-class in with only In clinical call by approximately territories In the come Financial driving while Buchanan, we for roughly our adoption over team, successful and commercial We hospital continued methodical exclusively territories will courses. plan then and on of TEST the that patient TCAR our dedicated the exceeding continuing Chief to accounts comments. carotid the will we commercial expect growth commercial Drive from the expand summary, X,XXX procedures over to and active we period. our to X,XXX XX achieved to XXXX towards